Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer InstituteSecondVersamune®platform candidate ...
Expression of the transmembrane mucin MUC1 is upregulated in response to chronic inflammation. Aberrant overexpression of transmembrane mucins is associated with diverse human carcinomas and ...
Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated mucin-1 (TA-MUC1) antibody, from Glycotope for $132.5m. The gatipotuzumab ...